Detecting adverse drug reactions for the drug Simvastatin by Liu, Yihui & Aickelin, Uwe
2012 Fourth International Conference on Multimedia Information Networking and Security
Detect adverse drug reactions for drug Simvastatin
Yihui • 1,11.1 1 2 Uwe Aickelin2
'Institute of Intelligent Information Processing 2Department of Computer Science,
Shandong Polytechnic University, China University of Nottingham,
UKYihui liu 2005@yahoo.co.uk
II. FEATUREMATRIXANDFEATURESELECTION
Abstract—Adverse drug reaction (ADR) is widely
concerned for public health issue. In this study we
propose an original approach to detect the ADRs using
feature matrix and feature selection. The experiments are
carried out on the drug Simvastatin. Major side effects
for the drug are detected and better performance is
achieved compared to other computerized methods. The
detected ADRs are based on the computerized method,
further investigation is needed.
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I. INTRODUCTION
Adverse drug reaction (ADR) is widely concerned for
public health issue. ADRs are one of most common causes to
withdraw some drugs from market [1 ]. Now two major
methods for detecting ADRs are spontaneous reporting
system (SRS) [ 2 , 3 ], and prescription event monitoring
(PEM) [ 4 , 5 ]. The World Health Organization (WHO)
defines a signal in pharmacovigilance as "any reported
information on a possible causal relationship between an
adverse event and a drug, the relationship being unknown or
incompletely documented previously"[ 6]. For spontaneous
reporting system, many machine learning methods are used
to detect ADRs, such as Bayesian confidence propagation
neural network (BCPNN) [7], decision support method [8],
genetic algorithm [9], knowledge based approach [10], etc.
One limitation is the reporting mechanism to submit ADR
reports [8], which has serious underreporting and is not able
to accurately quantify the corresponding risk. Another
limitation is hard to detect ADRs with small number of
occurrences of each drug-event association in the database.
In this paper we propose feature selection approach to
detect ADRs from The Health Improvement Network
(THIN) database. First feature matrix, which represents the
medical events for the patients before and after taking drugs,
is created by linking patients' prescriptions and
corresponding medical events together. Then significant
features are selected based on feature selection methods,
comparing the feature matrix before patients take drugs with
one after patients take drugs. Finally the significant ADRs
can be detected from thousands of medical events based on
corresponding features. Experiments are carried out on the
drug Simvastatin. Good performance is achieved.
A. The Extraction of Feature Matrix
To detect the ADRs of drugs, first feature matrix is
extracted from THIN database, which describes the medical
events that patients occur before or after taking drugs. Then
feature selection method of Student's t-test is performed to
select the significant features from feature matrix containing
thousands of medical events. Figure 1 shows the process to
detect the ADRs using feature matrix. Feature matrix A
describes the medical events for each patient during 60 days
before they take drugs. Feature matrix B reflects the
medical events during 60 days after patients take drugs. In
order to reduce the effect of the small events, and save the
computation time and space, we set 100 patients as a group.
Matrix X and Y are feature matrix after patients are divided
into groups.
Matrix X
Figure 1. The process to detect ADRs. Matrix A and B are
feature matrix before patients take drugs or after patients take
drugs. The time period of observation is set to 60 days.
Matrix X and Y are feature matrix after patients are divided
into groups. We set 100 patients as one group.
B. Medical Events and Readcodes
Medical events or symptoms are represented by medical
codes or Readcodes. There are 103387 types of medical
events in "Readcodes" database. The Read Codes used in
general practice (GP), were invented and developed by Dr
James Read in 1982. The NHS (National Health Service) has
expanded the codes to cover all areas of clinical practice.
The code is hierarchical from left to right or from level 1 to
level 5. It means that it gives more detailed information from
level 1 to level 5. Table 1 shows the medical symptoms
based on Readcodes at level 3 and at level 5. 'Other soft
tissue disorders' is general term using Readcodes at level 3.
`Foot pain', 'Heel pain', etc., give more details using
Readcodes at level 5.
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C. Feature Selection Based on Student's t-test
Feature extraction and feature selection are widely used
in biomedical data processing [11-18]. In our research we
use Student's t-test [19] feature selection method to detect
the significant ADRs from thousands of medical events.
Student's t-test is a kind of statistical hypothesis test based
on a normal distribution, and is used to measure the
difference between two kinds of samples.
TABLE I.
MEDICAL EVENTS BASED ON READCODES AT LEVEL 3 AND LEVEL 5.
Level Readcodes Medical events
Level 3 N24..00 Other soft tissue disorders
Muscle N245.16 Leg pain
pain N245111 Toe pain
Level 5 N245.13 Foot pain
N245700 Shoulder pain
N245.15 Heel pain
D. Other Parameters
The variable of ratio R, is defined to evaluate significant
changes of the medical events, using ratio of the patient
number after taking the drug to one before taking the drug.
The variable R2 represents the ratio of patient number after
taking the drug to the number of whole population having one
particular medical symptom.
The ratio variables R, and R2 are defined as follows:
N /
/NB i f NB #0;
NA if NB= 0;
R2 = NA I N
where NB and NA represent the numbers of patients
before or after they take drugs for having one particular
medical event respectively. The variable N represents the
number of whole population who take drugs.
III. EXPERIMENTS AND RESULTS
Simvastatin [20], under the trade name Zocor, is a
hypolipidemic drug used to control elevated cholesterol, or
hypercholesterolemia. It is a member of the statin class of
pharmaceuticals. Simvastatin has side effects [20,21,22]:
severe allergic reactions (rash; hives; itching; difficulty
breathing; tightness in the chest; swelling of the mouth, face,
lips, or tongue; unusual hoarseness); burning, numbness, or
tingling; change in the amount of urine produced; confusion;
dark or red-colored urine; decreased sexual ability;
depression; dizziness; fast or irregular heartbeat; fever, chills,
or persistent sore throat; joint pain; loss of appetite; memory
problems; muscle pain, tenderness, or weakness (with or
without fever and fatigue); pale stools; red, swollen, blistered,
or peeling skin; severe or persistent nausea or stomach or
back pain; shortness of breath; trouble sleeping; unusual
bruising or bleeding; unusual tiredness or weakness;
vomiting; yellowing of the skin or eyes.
14905 patients from 20GP data in THIN database are
taking Simvastatin, and 13060 medical events are obtained
based on Readcodes at level 1-5. After grouping them,
149x13060 feature matrix is obtained. For Readcodes at level
1-3, 149x2693 feature matrix is obtained.
Table 2 shows the top 30 detected results in ascending
order of p value of Student's t-test, using Readcodes at level
1-5 and at level 1-3. The detected results are using p value
less than 0.05, which represent the significant change after
patients take the drug. Table 3 shows the results in
descending order of the ratio of the number of patients after
taking the drug to one before taking the drug. Table 4 shows
potential ADRs related cancer for Simvastatin. The detected
ADRs are based on our computerized method, further
investigation is needed.
It is clear that our detected results are consistent with
published side effects for statin drugs [21, 22]. Major ADRs
of 'muscle and musculoskeletal' events for statin drugs are
detected not only based on Readcodes at level 1-5, but also
based on Readcodes at level 1-3.
IV. CONCLUSIONS
In this study we propose a novel method to successfully
detect the ADRs using feature matrix and feature selection. A
feature matrix, which characterizes the medical events before
patients take drugs or after patients take drugs, is created
from THIN database. The feature selection method of
Student's t-test is used to detect the significant features from
thousands of medical events. The significant ADRs, which
are corresponding to significant features, are detected.
Experiments are performed on the drug Simvastatin.
Compared to other computerized method, our proposed
method achieves good performance.
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TABLEII.THETOP 20ADRSFORSIMVASTATINBASEDON P VALUEOFSTUDENT'ST-TEST.
Rank Readcodes Medical events NB NA R1 R2
Level
1-5
1 1Z12.00 Chronic kidney disease stage 3 185 1095 5.92 7.35
2 M03z000 C,ellulitis NOS 98 503 5.13 3.37
3 F4C0.00 Acute conjunctivitis 113 525 4.65 3.52
4 N131.00 Cervicalgia - pain in neck 140 609 4.35 4.09
5 1106z000 Chest infection NOS 284 1201 4.23 8.06
6 N143.00 Sciatica 83 366 4.41 2.46
7 F46..00 Cataract 40 312 7.80 2.09
8 1M10.00 Knee pain 198 762 3.85 5.11
9 A53..11 Shingles 41 262 6.39 1.76
10 C34..00 Gout 107 381 3.56 2.56
11 1A55.00 Dysuria 70 308 4.40 2.07
12 N245.17 Shoulder pain 185 717 3.88 4.81
13 F45..00 Glaucoma 20 148 7.40 0.99
14 K190.00 Urinary tract infection, site not specified 128 607 4.74 4.07
15 F501.00 Infective otitis extema 89 372 4.18 2.50
16 1D14.00 C/O: a rash 152 689 4.53 4.62
17 N094K12 Hip pain 96 461 4.80 3.09
18 1832.11 Ankle swelling symptom 34 190 5.59 1.27
19 1C9..00 Sore throat symptom 97 410 4.23 2.75
20 B33..11 Basal cell carcinoma 42 212 5.05 1.42
Level
1-3
1 1106..00 Acute bronchitis and bronchiolitis 598 2221 3.71 14.90
2 1Z1..00 Chronic renal impairment 213 1286 6.04 8.63
3 171..00 Cough 571 2192 3.84 14.71
4 N24..00 Other soft tissue disorders 807 2643 3.28 17.73
5 N21..00 Peripheral enthesopathies and allied syndromes 265 1054 3.98 7.07
6 1105..00 Other acute upper respiratory infections 213 1074 5.04 7.21
7 M03..00 Other cellulitis and abscess 140 659 4.71 4.42
8 F4C..00 Disorders of conjunctiva 147 731 4.97 4.90
9 173..00 Breathlessness 461 1403 3.04 9.41
10 19F..00 Diarrhoea symptoms 189 861 4.56 5.78
11 K19..00 Other urethral and urinary tract disorders 221 1010 4.57 6.78
12 183..00 Oedema 177 795 4.49 5.33
13 N09..00 Other and unspecified joint disorders 355 1413 3.98 9.48
14 N13..00 Other cervical disorders 146 648 4.44 4.35
15 F46..00 Cataract 67 435 6.49 2.92
16 1B1..00 General nervous symptoms 437 1413 3.23 9.48
17 J57..00 Other disorders of intestine 75 361 4.81 2.42
18 N14..00 Other and unspecified back disorders 246 984 4.00 6.60
19 1M1..00 Pain in lower limb 228 851 3.73 5.71
20 1D1..00 GO: a general symptom 317 1278 4.03 8.57
Variable NB and NA represent the numbers of patients before or after they take drugs for having one particular medical event Variable R1represents the ratio of the
numbers of patients after taking drugs to the numbers of patients before taking drugs. Variable R2 represents the ratio of the numbers of patients after taking drugs to
the number of the whole population.
TABLEIII.THETOP20ADRSFORSIMVASTATINBASEDONDESCENDINGORDEROFR1VALUE.
Rank Readcodes Medical events NB NA R1 R2
Level 1-5
1 1Z1E.00 Chronic kidney disease stage 3A without proteinuria 0 40 40.00 0.27
2 Eu32000 [X]Mild depressive episode 1 39 39.00 0.26
3 C106.00 Diabetes mellitus with neurological manifestation 1 39 39.00 0.26
4 Eu32100 [X]Moderate depressive episode 0 27 27.00 0.18
5 SK17100 Other leg injury 1 26 26.00 0.17
6 11120.11 Catarrh unspecified 0 26 26.00 0.17
7 S646000 Minor head injury 2 51 25.50 0.34
8 1125..00 Bronchopneumonia due to unspecified organism 1 24 24.00 0.16
9 173L.00 MRC Breathlessness Scale: grade 5 0 22 22.00 0.15
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10 16D1.00 Recurrent falls 0 21 21.00 0.14
11 B32..00 Malignant melanoma of skin 1 20 20.00 0.13
12 E290000 Grief reaction 1 20 20.00 0.13
13 J4z0.00 Non-infective gastritis NOS 1 20 20.00 0.13
14 SN15.00 Chilblains 1 20 20.00 0.13
15 M220.00 Cutaneous horn 1 20 20.00 0.13
16 1B1E.00 Hallucinations 1 19 19.00 0.13
17 1151..00 Pleurisy 1 19 19.00 0.13
18 SE46.00 Traumatic haematoma 0 19 19.00 0.13
19 1D12.00 CIO: stiffness 1 19 19.00 0.13
20 B834.00 Carcinoma in situ of prostate 1 18 18.00 0.12
Level 1-3
1 1125..00 Bronchopneumonia due to unspecified organism 1 24 24.00 0.16
2 161..00 Appetite symptom 1 23 23.00 0.15
3 B32..00 Malignant melanoma of skin 1 22 22.00 0.15
4 U60..00 [X]Drugs/meds/biol subs caus adverse effects in therap use 2 37 18.50 0.25
5 J12..00 Duodenal ulcer - (DU) 2 37 18.50 0.25
6 N....00 Musculoskeletal and connective tissue diseases 0 16 16.00 0.11
7 D0...00 Deficiency anemias 2 31 15.50 0.21
8 B57..00 Secondary malig neop of respiratory and digestive systems 0 15 15.00 0.10
9 K23..00 Hydrocele 2 29 14.50 0.19
10 F4...00 Disorders of eye and adnexa 5 65 13.00 0.44
11 B17..00 Malignant neoplasm of pancreas 0 13 13.00 0.09
12 17...00 Respiratory symptoms 0 13 13.00 0.09
13 G8y..00 Other specified vein, lymphatic or other circulatory 1 13 13.00 0.09
14 C26..00 Vitamin B-complex deficiency 3 37 12.33 0.25
15 S5z..00 Sprains and strains NOS 2 24 12.00 0.16
16 SF3..00 Crush injury, lower limb 0 12 12.00 0.08
17 B11..00 Malignant neoplasm of stomach 1 12 12.00 0.08
18 H41..00 Asbestosis 1 12 12.00 0.08
19 F43..00 Chorioretinal inflammations scars and other disorders 1 12 12.00 0.08
20 F5...00 Diseases of the ear and mastoid process 1 12 12.00 0.08
TABLEW.THEPOTENTIALADRSRELATEDTOCANCERFORSIMVASTATINBASEDONPVALUEOFSTUDENT'ST-TEST.
Rank Readcodes Medical events NB NA R1 R2
1 B33..00 Other malignant neoplasm of skin 46 241 5.24 1.62
2 B34..00 Malignant neoplasm of female breast 8 72 9.00 0.48
3 B76..00 Benign neoplasm of skin 75 240 3.20 1.61
4 BB5..00 [M]Adenomas and adenocarcinomas 7 69 9.86 0.46
5 BB2..00 [M]Papillary and squamous cell neoplasms 7 66 9.43 0.44
6 B46..00 Malignant neoplasm of prostate 23 105 4.57 0.70
7 B22..00 Malignant neoplasm of trachea, bronchus and lung 5 47 9.40 0.32
8 B32..00 Malignant melanoma of skin 1 22 22.00 0.15
9 170..00 Suspected malignancy 4 33 8.25 0.22
10 BB3..00 [M]Basal cell neoplasms 4 30 7.50 0.20
11 B8...00 Carcinoma in situ 12 41 3.42 0.28
12 B57..00 Secondary malig neop of respiratory and digestive systems 0 15 15.00 0.10
13 B83..00 Carcinoma in situ of breast and genitourinary system 4 29 7.25 0.19
14 B13..00 Malignant neoplasm of colon 7 30 4.29 0.20
15 B17..00 Malignant neoplasm of pancreas 0 13 13.00 0.09
16 B62..00 Other malignant neoplasm of lymphoid and histiocytic tissue 2 17 8.50 0.11
17 B11..00 Malignant neoplasm of stomach 1 12 12.00 0.08
18 B49..00 Malignant neoplasm of urinary bladder 3 19 6.33 0.13
19 B14..00 Malignant neoplasm of rectum, rectosigmoid junction and anus 5 24 4.80 0.16
20 B63..00 Multiple myeloma and immunoproliferative neoplasms 0 8 8.00 0.05
21 B59..00 Malignant neoplasm of unspecified site 1 11 11.00 0.07
22 B10..00 Malignant neoplasm of oesophagus 3 12 4.00 0.08
23 BB4..00 [M]Transitional cell papillomas and carcinomas 6 17 2.83 0.11
24 B1 z..00 Malig neop oth/ill-defined sites digestive tract/peritoneum 0 5 5.00 0.03
25 B58..00 Secondary malignant neoplasm of other specified sites 2 9 4.50 0.06
26 B44..00 Malignant neoplasm of ovary and other uterine adnexa 0 4 4.00 0.03
27 B81..00 Carcinoma in situ of respiratory system 0 4 4.00 0.03
28 B56..00 Secondary and unspecified malignant neoplasm of lymph
nodes
0 4 4.00 0.03
29 B71..00 Benign neoplasm of other parts of digestive system 10 23 2.30 0.15
30 BBQ..00 [M]Germ cell neoplasms 0 3 3.00 0.02
